New treatments for a specific type of aggressive brain tumor
New Therapeutic Approaches for Stratified High-REST GBM Subtype
This study is looking at a tough type of brain tumor called glioblastoma to find better treatments that are specially designed for patients with certain tumor characteristics, especially those with high levels of a protein linked to worse outcomes, so we can help improve survival rates for everyone affected by this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10993583 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma (GBM), a highly aggressive brain tumor that varies in its molecular characteristics. The study aims to develop targeted therapies based on the specific subtype of GBM, particularly those with high levels of the REST protein, which are associated with poorer patient outcomes. By understanding the biology of cancer stem-like cells within these tumors, the researchers hope to create more effective treatment options that could improve survival rates for patients. The approach involves evaluating the unique properties of these tumor subtypes to tailor therapies accordingly.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma, particularly those whose tumors exhibit high levels of REST expression.
Not a fit: Patients with glioblastoma who do not have the high REST subtype may not benefit from the specific therapies developed in this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with glioblastoma, potentially improving survival rates.
How similar studies have performed: Other research has shown promise in targeting specific molecular subtypes of glioblastoma, indicating that this approach could be a meaningful advancement in treatment.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Majumder, Sadhan — University of Tx Md Anderson Can Ctr
- Study coordinator: Majumder, Sadhan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.